{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:10:23Z","timestamp":1771596623024,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"publisher","award":["SUBZ.D230.25.047"],"award-info":[{"award-number":["SUBZ.D230.25.047"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>(1) Background: Meyerozyma guilliermondii is a yeast species widely distributed in the natural environment and one of the rare emerging pathogens capable of causing difficult to treat, severe infections. The species\u2019 susceptibility profile is not fully defined; however, the species could be more prone to develop resistance than other Candida species. The objective of this research was to determine the susceptibility of a local collection of Meyerozyma guilliermondii clinical isolates to classical antifungal drugs as well as a new one\u2014manogepix. (2) Methods: The study included 20 clinical isolates identified using the MALDI\u2013TOF method followed with sequencing of ITS1-2 region of DNA. Overall, the susceptibility to 12 antifungal drugs was tested. Nine drugs (amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, and micafungin) were assessed using the MICRONAUT\u2013AT test. The susceptibility to the new drug, manogepix, as well as isavuconazole, clotrimazole and anidulafungin, was determined using the microdilution method recommended by EUCAST. Additionally, anidulafungin and voriconazole MIC was also examined with commercial gradient tests. (3) Results: Overall, the isolates showed low MIC values for amphotericin B (0.125 to 1 mg\/L) and for flucytosine (\u22640.06 to 32 mg\/L), with the exception of one isolate with a high MIC value. The MIC ranges for azoles were 2\u201364 mg\/L (fluconazole), 0.008\u20130.5 mg\/L (voriconazole), \u22640.03\u2013\u22654 mg\/L (itraconazole) and 0.008\u20130.5 mg\/L (posaconazole). One isolate showed non-WT phenotype to all tested azoles. For anidulafungin, the MIC values ranged from \u22640.06 to 0.25 mg\/L; however, in the reference method, higher values were observed, but they did not exceed 2 mg\/L (ECOFF value). For manogepix, the MIC values ranged from 0.002 to 0.125 mg\/L. Finally, the comparison of the obtained and published susceptibility data was conducted. (4) Conclusions: The data obtained in this study are consistent with reports by other authors and indicate that resistance to azoles or 5-fluorocytosine among clinical isolates of Meyerozyma guilliermondii should be considered. The low MIC values of manogepix suggest the potentially good efficacy of this drug against Meyerozyma guilliermondii species.<\/jats:p>","DOI":"10.3390\/pathogens15020235","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:08:23Z","timestamp":1771592903000},"page":"235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data"],"prefix":"10.3390","volume":"15","author":[{"given":"Aleksandra","family":"G\u00f3rzy\u0144ska","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Microbiology and Parasitology, Wroc\u0142aw Medical University, Borowska 211a, 50-556 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6182-4254","authenticated-orcid":false,"given":"Daria","family":"Konarska","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Microbiology and Parasitology, Wroc\u0142aw Medical University, Borowska 211a, 50-556 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Korzeniowska-Kowal","sequence":"additional","affiliation":[{"name":"Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, St. Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wzorek","sequence":"additional","affiliation":[{"name":"Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, St. Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Pencakowski","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biology and Biotechnology, Wroc\u0142aw Medical University, 50-556 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0906-2377","authenticated-orcid":false,"given":"Urszula","family":"Nawrot","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Microbiology and Parasitology, Wroc\u0142aw Medical University, Borowska 211a, 50-556 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jhin.2001.1151","article-title":"Non-albicans Candida spp. causing fungaemia: Pathogenicity and antifungal resistance","volume":"50","author":"Krcmery","year":"2002","journal-title":"J. Hosp. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1439-0507.2010.01960.x","article-title":"What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast","volume":"54","author":"Savini","year":"2011","journal-title":"Mycoses"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.fm.2014.12.014","article-title":"Phenotypic and molecular diversity of Meyerozyma guilliermondii isolates isolated from food and other environmental niches, hints for an incipient speciation","volume":"48","author":"Corte","year":"2015","journal-title":"Food Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1146\/annurev-micro-032521-015858","article-title":"Candida auris Genetics and Emergence","volume":"77","author":"Chowdhary","year":"2023","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Motta, J.C., Rivas-Pinedo, P., and Onate, J.M. (2025). Changing climate, changing Candida: Environmental and social pressures on invasive candidiasis and antifungal resistance in Latin America. J. Fungi, 11.","DOI":"10.20944\/preprints202507.0969.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23639","DOI":"10.1074\/jbc.M301044200","article-title":"GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast","volume":"278","author":"Umemura","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e01387-19","DOI":"10.1128\/AAC.01387-19","article-title":"Evaluation of resistance development to the Gwt1 inhibitor Manogepix (APX001A) in Candida species","volume":"64","author":"Kapoor","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e01057-24","DOI":"10.1128\/jcm.01057-24","article-title":"Candida guilliermondii fungemia: A 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center","volume":"62","author":"McHugh","year":"2024","journal-title":"J. Clin. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"myaf087","DOI":"10.1093\/mmy\/myaf087","article-title":"Candidemia caused by Meyerozyma guilliermondii species complex in patients with cancer: A systematic review of case reports","volume":"63","author":"Tang","year":"2025","journal-title":"Med. Mycol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/IDR.S504516","article-title":"Analysis of antifungal drug resistance among Candida spp. and other pathogenic yeasts isolated from patients in eastern Poland: Diagnostic problems","volume":"18","author":"Olender","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"G\u00f3rzy\u0144ska, A., Kondracka, K., Korzeniowska-Kowal, A., and Nawrot, U. (2024). Antifungal susceptibility of Saccharomyces cerevisiae isolated from clinical specimens. Pathogens, 13.","DOI":"10.3390\/pathogens13030248"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3109\/13693780903531579","article-title":"Optimized 5-hour multiplex PCR test for the detection of tinea unguium: Performance in a routine PCR laboratory","volume":"48","author":"Nielsen","year":"2010","journal-title":"Med. Mycol."},{"key":"ref_13","unstructured":"Innis, M.A., Gelfand, D.H., Sninsky, J.J., and White, T.J. (1990). Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. PCR Protocols: A Guide to Methods and Applications, Academic Press Inc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"msae263","DOI":"10.1093\/molbev\/msae263","article-title":"MEGA12: Molecular Evolutionary Genetic Analysis Version 12 for Adaptive and Green Computing","volume":"41","author":"Kumar","year":"2024","journal-title":"Mol. Biol. Evol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"W465","DOI":"10.1093\/nar\/gkn180","article-title":"Phylogeny.fr: Robust phylogenetic analysis for the non-specialist","volume":"36","author":"Dereeper","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_16","first-page":"678","article-title":"Estimation of the number of nucleotide substitutions when there are strong transition-transversion and G+C-content biases","volume":"9","author":"Tamura","year":"1992","journal-title":"Mol. Biol. Evol."},{"key":"ref_17","unstructured":"Guinea, J., Meletiadis, J., Arikan-Akdagli, S., Giske, C., Muehlethaler, K., Arendrup, M.C., and the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) (2023, December 10). Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Files\/EUCAST_E.Def_7.4_Yeast_definitive_revised_2023.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5021\/ad.2015.27.6.715","article-title":"Antifungal susceptibility testing with Etest for Candida species isolated from patients with oral candidiasis","volume":"27","author":"Song","year":"2015","journal-title":"Ann. Dermatol."},{"key":"ref_19","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2025, September 08). Overview of Antifungal ECOFFs and Clinical Breakpoints for Yeasts and Moulds\u2014Valid from 26 June 2025. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Clinical_breakpoints\/AFST_BP-ECOFF_v6.0_non-protected_Final_26_Jun_2025_MaCA.pdf."},{"key":"ref_20","first-page":"105086","article-title":"The susceptibility of Meyerozyma guilliermondii and Kluyveromyces marxianus to manogepix and other antifungal drugs; In ESCMID Global Abstract Book 2025","volume":"2","author":"Konarska","year":"2025","journal-title":"CMI Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"myad056","DOI":"10.1093\/mmy\/myad056","article-title":"Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009\u20132020","volume":"61","author":"Nishida","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0511522","DOI":"10.1128\/spectrum.05115-22","article-title":"Emergence of cryptic species and clades of Meyerozyma guilliermondii species complex exhibiting limited in vitro susceptibility to antifungals in patients with candidemia","volume":"11","author":"Francisco","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e00429-20","DOI":"10.1128\/AAC.00429-20","article-title":"Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jmii.2016.08.015","article-title":"Clinical features. antifungal susceptibility. and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan","volume":"51","author":"Tseng","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s42770-022-00813-2","article-title":"Meyerozyma guilliermondii species complex: Review of current epidemiology. antifungal resistance. and mechanisms","volume":"53","author":"Ghasemi","year":"2022","journal-title":"Braz. J. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/PL00011265","article-title":"Flucytosine primary resistance in Candida species and Cryptococcus neoformans","volume":"20","author":"Mellado","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_27","unstructured":"(2024, July 03). EUCAST Guidance on Interpretation of MICs for Rare Yeast Without Breakpoints in Breakpoint Tables. Available online: https:\/\/www.eucast.org\/fileadmin\/eucast\/pdf\/AFST\/guidance_documents\/EUCAST_guidance_for_Rare_yeast_with_no_breakpoints_final_clean_19-06-2024.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.mycmed.2019.08.001","article-title":"Antifungal susceptibility and virulence factors of Candida spp. isolated from blood cultures","volume":"29","author":"Sriphannam","year":"2019","journal-title":"J. Mycol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.00865-06","article-title":"Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program","volume":"44","author":"Pfaller","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.diagmicrobio.2006.10.011","article-title":"Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: Results of a multicenter study conducted in S\u00e3o Paulo, Brazil, 1995\u20132003","volume":"57","author":"Machado","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Desnos-Ollivier, M., Bretagne, S., Boulli\u00e9, A., Gautier, C., Dromer, F., Lortholary, O., and French Mycoses Study Group (2019). Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015\u20132017). Clin. Microbiol. Infect., 25.","DOI":"10.1016\/j.cmi.2019.02.007"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e0245322","DOI":"10.1128\/spectrum.02453-22","article-title":"Epidemiology and antifungal susceptibility of Candida species isolated from 10 tertiary care hospitals in Iran","volume":"10","author":"Badiee","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Frej-M\u0105drzak, M., Golec, S., W\u0142odarczyk, K., Choroszy-Kr\u00f3l, I., and Nawrot, U. (2021). Susceptibility to clotrimazole of Candida spp. isolated from the genitourinary system-a single center study. Pathogens, 10.","DOI":"10.3390\/pathogens10091142"},{"key":"ref_34","unstructured":"(2024, July 03). European Committee on Antimicrobial Susceptibility Testing Routine and Extended Internal Quality Control for MIC Determination and Agar Dilution for Yeasts, Moulds and Dermatophytes as Recommended by EUCAST. Available online: https:\/\/www.eucast.org\/fileadmin\/eucast\/pdf\/AFST\/QC\/EUCAST_AFST_QC_v_7.0.pdf."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/2\/235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:21:19Z","timestamp":1771593679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/2\/235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pathogens15020235"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15020235","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}